Laquinimod
- On May 23, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reaffirmed its negative opinion on the market application for laquinimod (Nerventra®)
- CHMP confirmed that the risks observed in animal studies do not prevent a registration for treatment in humans
- The ongoing US pivotal clinical study CONCERTO is continuing according to plan. The results are expected in 2016
Tasquinimod
- The Phase III study 10TASQ10 is proceeding according to plan
ANYARA
- Development program for further clinical development outlined in collaboration with regulatory authorities
- All project activities will be put on hold until further notice
Paquinimod (57-57)
- In June 2014, data related to the drug candidate paquinimod for the treatment of systemic sclerosis was presented at the scientific conference "EULAR Annual European Congress of Rheumatology"
ISI
- Expansion of the patent portfolio
- CD selection expected in 2015
Financial summary
| MSEK | April - June | January - June | Full Year | ||||
| 2014 | 2013 | 2014 | 2013 | 2013 | |||
| Net sales | 2.7 | 2.5 | 4.9 | 5.0 | 116.0 | ||
| Operating loss | -57.9 | -79.5 | -117.2 | -156.5 | -209.0 | ||
| Loss for the period | -57.7 | -81.2 | -117.9 | -159.2 | -212.1 | ||
| Loss per share (SEK) | -0.77 | -1.08 | -1.57 | -2.18 | -2.87 | ||
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00 The report is also available at www.activebiotech.com |
